Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
about
Optimizing contrast-enhanced magnetic resonance imaging characterization of brain metastases: relevance to stereotactic radiosurgery.Use of contrast agents in oncological imaging: magnetic resonance imaging.ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.Contrast-enhanced magnetic resonance imaging in pediatric patients: review and recommendations for current practiceMR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channelsThe seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla.Emerging role of brain metastases in the prognosis of breast cancer patients.MR imaging in multiple sclerosis: review and recommendations for current practice.Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study).Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications?Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features.Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine.Comparison of gadobenate dimeglumine and gadodiamide in the evaluation of spinal vascular anatomy with MR angiography.Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer.Gadobenate dimeglumine (MultiHance) in MR angiography: an in-vitro phantom comparison with gadopentetate dimeglumine (Magnevist) at different concentrations.The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.Fat-saturated post gadolinium T1 imaging of the brain in multiple sclerosis.Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma.Contrast-enhanced MRI of the inner ear after intratympanic injection of meglumine gadopentetate or gadodiamide hydrate
P2860
Q30586979-BB6DB7E4-C1D7-4CE5-9CAA-B5B3C0BCB747Q30669419-6A69CB3D-5DE9-481B-ABA3-2A64028FA53EQ30833655-37A8300D-84F8-4D52-BF59-FCED2D3F5646Q33873443-F76B8790-2D9B-4720-8BF8-5E18869432B1Q34053148-9D56D77D-ECE5-4FEE-9021-A4843B1B3529Q34105366-BEFAA3FE-CA05-4B64-B53F-55D4145A887FQ34784896-DAB197C9-E4F6-41C7-97DD-727DFF48EF13Q36295407-50E7A100-003A-47DB-953F-5CAA905BDDE5Q37314667-BE44D159-CB94-478B-A155-919E9589CF45Q37356182-0394FD40-754E-4981-85A5-94215649E091Q37658010-6C78AEA3-97DA-4DB2-8F29-D595D36D0E19Q38078314-A8F92370-57B0-4644-B49F-39D076B3C27EQ38213840-84BCA06E-C0E2-49A5-8ECD-3A371966C177Q39197153-1A9B334B-75D0-4184-98AE-598F95CD791BQ40219525-2A0FE2AA-9D66-492D-B208-DEF8CB6147EBQ43124662-8D540283-3A8A-4468-B699-5B9F4E21E321Q43181515-393B281E-FD2E-4589-94B1-06C33CA741A4Q43201167-8D133BF8-E5BD-42F1-9CF1-0300A900E6D2Q45173741-4073AF55-5C58-4C62-B8C0-24727212CB48Q45931214-1A10C0C7-B3D3-4799-8FC8-27B0D80CAB88Q46453502-0C487D22-C833-4949-9397-B80EF1B50438Q48157270-AB96697F-9F21-4491-ADC5-43C10D956A28Q48177044-A60EC2E9-1F1A-425F-A0AB-DF3420908A38Q48786983-45C8B60D-C2E5-444B-B379-609F41C9E8FCQ51474941-DCD70CDA-DFFD-4E4E-A57F-B130098CED57Q51495475-33E8DF13-CE7E-4C39-8B29-8EE7C96D217AQ57185308-1AA44A05-E2CF-47EC-AA62-88914EF47524
P2860
Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@en
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@nl
type
label
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@en
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@nl
prefLabel
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@en
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@nl
P2093
P2860
P356
P1476
Contrast-enhanced MR imaging o ...... imeglumine versus gadodiamide.
@en
P2093
C Colosimo
F J Wippold
H A Rowley
I M Schmalfuss
J Ruscalleda
M Gallucci
P2860
P304
P356
10.3174/AJNR.A1185
P577
2008-07-03T00:00:00Z